NASDAQ:MDWD Mediwound Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mediwound Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.60 -0.08 (-2.17 %) (As of 09/21/2020 12:10 PM ET) Add Compare Share Today's Range$3.58Now: $3.60▼$3.6650-Day Range$3.09MA: $3.54▼$4.1452-Week Range$1.44Now: $3.60▼$4.44Volume1,000 shsAverage Volume112,794 shsMarket Capitalization$97.96 millionP/E RatioN/ADividend YieldN/ABeta1.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMediwound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Mediwound has a forecasted upside of 69.8% from its current price of $3.68.Amount of Analyst CoverageMediwound has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesMediwound has received 367 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMediwound has received 330 “underperform” votes. (Add your “underperform” vote.)Community SentimentMediwound has received 52.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote “Outperform” if you believe MDWD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMediwound does not currently pay a dividend.Dividend GrowthMediwound does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mediwound insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 16.69% of the stock of Mediwound is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mediwound are expected to grow in the coming year, from ($0.40) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mediwound is -10.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mediwound is -10.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediwound has a P/B Ratio of 6.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD Previous Symbol CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972-8932-4010Debt Debt-to-Equity Ratio0.18 Current Ratio3.05 Quick Ratio2.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.79 million Price / Sales3.08 Cash Flow$0.13 per share Price / Cash Flow27.25 Book Value$0.56 per share Price / Book6.43Profitability EPS (Most Recent Fiscal Year)$0.08 Net Income$4.95 million Net Margins-48.34% Return on Equity-85.28% Return on Assets-30.63%Miscellaneous Employees73 Outstanding Shares27,211,000Market Cap$97.96 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $3.60 -0.08 (-2.17 %) (As of 09/21/2020 12:10 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MDWD News and Ratings via Email Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Mediwound (NASDAQ:MDWD) Frequently Asked Questions How has Mediwound's stock been impacted by Coronavirus? Mediwound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDWD shares have increased by 55.8% and is now trading at $3.60. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Mediwound? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mediwound. When is Mediwound's next earnings date? Mediwound is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Mediwound. How were Mediwound's earnings last quarter? Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.11). The biopharmaceutical company had revenue of $4.03 million for the quarter, compared to analyst estimates of $4.79 million. Mediwound had a negative net margin of 48.34% and a negative return on equity of 85.28%. View Mediwound's earnings history. What price target have analysts set for MDWD? 2 brokers have issued 1 year target prices for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next year. This suggests a possible upside of 73.6% from the stock's current price. View analysts' price targets for Mediwound. Are investors shorting Mediwound? Mediwound saw a increase in short interest in August. As of August 31st, there was short interest totaling 137,600 shares, an increase of 69.5% from the August 15th total of 81,200 shares. Based on an average daily volume of 160,400 shares, the short-interest ratio is presently 0.9 days. Approximately 0.6% of the company's shares are sold short. View Mediwound's Short Interest. Who are some of Mediwound's key competitors? Some companies that are related to Mediwound include Canopy Rivers (RIV), Chromadex (CDXC), Charlie's (CHUC), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), FSD Pharma (HUGE), Mannatech (MTEX), Sundial Growers (SNDL), Heyu Biological Technology (HYBT), True Drinks (TRUU), Glucose Health (GLUC), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF) and Tauriga Sciences (TAUG). View all competitors. What other stocks do shareholders of Mediwound own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Sorrento Therapeutics (SRNE), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Company (WFC), Geron (GERN), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC) and Idera Pharmaceuticals (IDRA). Who are Mediwound's key executives? Mediwound's management team includes the following people: Mr. Gal Cohen, Pres & CEO (Age 46)Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)Dr. Ety Klinger, Chief R&D Officer (Age 57) What is Mediwound's stock symbol? Mediwound trades on the NASDAQ under the ticker symbol "MDWD." Who are Mediwound's major shareholders? Mediwound's stock is owned by many different institutional and retail investors. Top institutional investors include Sargent Investment Group LLC (0.63%), Phoenix Holdings Ltd. (0.46%), Thomasville National Bank (0.08%), Harel Insurance Investments & Financial Services Ltd. (0.05%) and Meitav Dash Investments Ltd. (0.04%). Which institutional investors are selling Mediwound stock? MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Which institutional investors are buying Mediwound stock? MDWD stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Sargent Investment Group LLC, Thomasville National Bank, and Meitav Dash Investments Ltd.. How do I buy shares of Mediwound? Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mediwound's stock price today? One share of MDWD stock can currently be purchased for approximately $3.60. How big of a company is Mediwound? Mediwound has a market capitalization of $97.96 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe. What is Mediwound's official website? The official website for Mediwound is www.mediwound.com. How can I contact Mediwound? Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
